Moderna, Inc. reported insider transactions by Stephen Hoge involving the company’s common stock on July 15, 2026. The Form 4 shows that Hoge exercised stock options and sold a portion of the resulting or existing shares, with the sale conducted under a prearranged Rule 10b5-1 trading plan adopted on November 13, 2025. Hoge exercised an option to acquire 37,226 shares of Moderna common stock at an exercise price of $19.15 per share. The option was reported as fully vested and exercisable. Based on the stated exercise price, the exercise cost was approximately $712,878. The transaction would typically be reported with transaction code “M,” indicating the exercise or conversion of a derivative security into common stock. On the same date, Hoge sold 16,110 shares of Moderna common stock at $67.60 per share, a transaction typically reported with code “S” for an open-market or private sale. The sale generated approximately $1.09 million in gross proceeds. The filing notes that the reported transaction was effected pursuant to the November 2025 Rule 10b5-1 trading plan, a structure that allows insiders to schedule trades in advance. After the reported sale, Hoge directly owned 1,537,184 shares of Moderna common stock. The filing also reported 53,336 shares held indirectly by a trust for the benefit of Dr. Hoge’s spouse and children, with his spouse serving as trustee. Hoge disclaimed Section 16 beneficial ownership of those trust-held securities except to the extent of any pecuniary interest. In net terms, the option exercise and sale increased Hoge’s direct holdings by 21,116 shares on the reporting date: he acquired 37,226 shares through the option exercise and sold 16,110 shares. The filing was signed on July 16, 2026, by James Dillon as attorney-in-fact.